VTv Long Term Debt vs Total Revenue Analysis

VTVT Stock

USD 16.70 0.86 4.90%

VTv Therapeutics financial indicator trend analysis is much more than just breaking down vTv Therapeutics prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether vTv Therapeutics is a good investment. Please check the relationship between VTv Therapeutics Long Term Debt and its Total Revenue accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in vTv Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.

For more information on how to buy VTv Stock please use our How to Invest in VTv Therapeutics guide.

Long Term Debt vs Total Revenue

Long Term Debt vs Total Revenue Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of vTv Therapeutics Long Term Debt account and Total Revenue. At this time, the significance of the direction appears to have weak contrarian relationship.

The correlation between VTv Therapeutics' Long Term Debt and Total Revenue is -0.05. Overlapping area represents the amount of variation of Long Term Debt that can explain the historical movement of Total Revenue in the same time period over historical financial statements of vTv Therapeutics, assuming nothing else is changed. The correlation between historical values of VTv Therapeutics' Long Term Debt and Total Revenue is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Long Term Debt of vTv Therapeutics are associated (or correlated) with its Total Revenue. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Revenue has no effect on the direction of Long Term Debt i.e., VTv Therapeutics' Long Term Debt and Total Revenue go up and down completely randomly.

Correlation Coefficient

-0.05

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

Long Term Debt

Long-term debt is a debt that vTv Therapeutics has held for over one year. Long-term debt appears on vTv Therapeutics balance sheet and also includes long-term leases. The most common forms of long term debt are bonds payable, long-term notes payable, mortgage payable, pension liabilities, and lease liabilities. In the corporate world, long-term debt is generally used to fund big-ticket items, such as machinery, buildings, and land. The total of long-term debt reported on vTv Therapeutics balance sheet is the sum of the balances of all categories of long-term debt. Debt that is not due within the current year and is often considered to be financing activities that are to be repaid over several years.

Total Revenue

Total revenue comprises all receipts vTv Therapeutics generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.

Most indicators from VTv Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into vTv Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in vTv Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.

For more information on how to buy VTv Stock please use our How to Invest in VTv Therapeutics guide.At this time, VTv Therapeutics' Issuance Of Capital Stock is comparatively stable compared to the past year. Sales General And Administrative To Revenue is likely to gain to 11.59 in 2024, whereas Selling General Administrative is likely to drop slightly above 11.5 M in 2024.

	2021	2022	2023	2024 (projected)
Interest Expense	12K	15K	13K	12.4K
Depreciation And Amortization	89K	92K	90K	85.5K

Interest Expense Depreciation And Amortization

VTv Therapeutics fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Long Term Debt	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Short Term Investments	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross
Total Assets		-0.15	0.18	-0.27	0.23	-0.25	-0.28	-0.02	-0.67	0.46	0.35	0.96	-0.34	-0.04	-0.11	-0.18	0.96	0.31	0.85	-0.33	-0.02	-0.44	0.15	0.11	-0.08	-0.3
Short Long Term Debt Total	-0.15		-0.61	0.95	-0.79	-0.39	0.96	-0.07	0.82	-0.31	-0.02	-0.27	0.78	0.81	-0.81	-0.2	-0.26	-0.26	-0.3	-0.19	0.63	0.02	-0.3	-0.85	0.78	0.95
Other Current Liab	0.18	-0.61		-0.51	0.59	-0.02	-0.74	0.57	-0.53	0.43	0.66	0.23	-0.56	-0.37	0.53	0.12	0.23	0.55	0.29	0.05	-0.52	-0.02	0.02	0.69	-0.58	-0.73
Total Current Liabilities	-0.27	0.95	-0.51		-0.61	-0.48	0.9	-0.11	0.86	-0.15	-0.03	-0.37	0.73	0.67	-0.63	-0.39	-0.37	-0.25	-0.4	-0.17	0.39	0.13	-0.16	-0.66	0.58	0.91
Total Stockholder Equity	0.23	-0.79	0.59	-0.61		-0.1	-0.83	-0.18	-0.71	0.77	0.1	0.33	-0.75	-0.81	0.77	-0.42	0.32	0.26	0.37	0.14	-0.96	0.07	0.56	0.98	-0.99	-0.82
Other Liab	-0.25	-0.39	-0.02	-0.48	-0.1		-0.23	0.13	-0.14	-0.64	-0.34	-0.2	-0.27	-0.26	0.36	0.72	-0.2	0.16	-0.17	-0.1	0.19	-0.44	0.01	0.01	0.06	-0.18
Property Plant And Equipment Net	-0.28	0.96	-0.74	0.9	-0.83	-0.23		-0.18	0.87	-0.47	-0.26	-0.39	0.84	0.72	-0.73	-0.1	-0.39	-0.34	-0.41	-0.27	0.67	0.02	-0.23	-0.88	0.81	0.99
Current Deferred Revenue	-0.02	-0.07	0.57	-0.11	-0.18	0.13	-0.18		0.01	-0.21	0.61	-0.09	0.06	0.28	-0.02	0.48	-0.09	0.33	-0.23	0.15	0.23	0.09	-0.42	-0.05	0.18	-0.19
Net Debt	-0.67	0.82	-0.53	0.86	-0.71	-0.14	0.87	0.01		-0.5	-0.23	-0.77	0.82	0.61	-0.51	-0.04	-0.77	-0.27	-0.74	0.02	0.48	0.27	-0.23	-0.68	0.62	0.87
Retained Earnings	0.46	-0.31	0.43	-0.15	0.77	-0.64	-0.47	-0.21	-0.5		0.4	0.5	-0.47	-0.33	0.24	-0.75	0.5	0.2	0.5	0.13	-0.77	0.15	0.38	0.66	-0.71	-0.48
Accounts Payable	0.35	-0.02	0.66	-0.03	0.1	-0.34	-0.26	0.61	-0.23	0.4		0.36	-0.28	0.36	-0.22	0.03	0.36	0.37	0.37	0.11	-0.05	-0.01	-0.48	0.13	-0.05	-0.26
Cash	0.96	-0.27	0.23	-0.37	0.33	-0.2	-0.39	-0.09	-0.77	0.5	0.36		-0.53	-0.13	-0.02	-0.16	1.0	0.18	0.92	-0.28	-0.11	-0.45	0.07	0.21	-0.19	-0.39
Non Current Assets Total	-0.34	0.78	-0.56	0.73	-0.75	-0.27	0.84	0.06	0.82	-0.47	-0.28	-0.53		0.61	-0.61	0.03	-0.53	-0.2	-0.59	-0.08	0.61	0.29	-0.1	-0.75	0.72	0.8
Non Currrent Assets Other	-0.04	0.81	-0.37	0.67	-0.81	-0.26	0.72	0.28	0.61	-0.33	0.36	-0.13	0.61		-0.93	0.14	-0.13	-0.18	-0.19	-0.01	0.75	0.0	-0.63	-0.84	0.82	0.71
Other Assets	-0.11	-0.81	0.53	-0.63	0.77	0.36	-0.73	-0.02	-0.51	0.24	-0.22	-0.02	-0.61	-0.93		-0.04	-0.02	0.22	0.01	0.0	-0.75	-0.01	0.53	0.85	-0.82	-0.7
Long Term Debt	-0.18	-0.2	0.12	-0.39	-0.42	0.72	-0.1	0.48	-0.04	-0.75	0.03	-0.16	0.03	0.14	-0.04		-0.16	0.13	-0.12	0.01	0.56	-0.24	-0.45	-0.28	0.4	-0.1
Cash And Short Term Investments	0.96	-0.26	0.23	-0.37	0.32	-0.2	-0.39	-0.09	-0.77	0.5	0.36	1.0	-0.53	-0.13	-0.02	-0.16		0.18	0.92	-0.28	-0.11	-0.45	0.07	0.21	-0.18	-0.39
Net Receivables	0.31	-0.26	0.55	-0.25	0.26	0.16	-0.34	0.33	-0.27	0.2	0.37	0.18	-0.2	-0.18	0.22	0.13	0.18		0.28	-0.22	-0.18	-0.28	0.32	0.31	-0.22	-0.35
Common Stock Shares Outstanding	0.85	-0.3	0.29	-0.4	0.37	-0.17	-0.41	-0.23	-0.74	0.5	0.37	0.92	-0.59	-0.19	0.01	-0.12	0.92	0.28		-0.29	-0.17	-0.47	0.05	0.27	-0.24	-0.42
Short Term Investments	-0.33	-0.19	0.05	-0.17	0.14	-0.1	-0.27	0.15	0.02	0.13	0.11	-0.28	-0.08	-0.01	0.0	0.01	-0.28	-0.22	-0.29		-0.17	0.6	-0.24	0.19	-0.19	-0.3
Non Current Liabilities Total	-0.02	0.63	-0.52	0.39	-0.96	0.19	0.67	0.23	0.48	-0.77	-0.05	-0.11	0.61	0.75	-0.75	0.56	-0.11	-0.18	-0.17	-0.17		-0.18	-0.58	-0.94	0.98	0.65
Inventory	-0.44	0.02	-0.02	0.13	0.07	-0.44	0.02	0.09	0.27	0.15	-0.01	-0.45	0.29	0.0	-0.01	-0.24	-0.45	-0.28	-0.47	0.6	-0.18		-0.19	0.12	-0.13	-0.04
Other Current Assets	0.15	-0.3	0.02	-0.16	0.56	0.01	-0.23	-0.42	-0.23	0.38	-0.48	0.07	-0.1	-0.63	0.53	-0.45	0.07	0.32	0.05	-0.24	-0.58	-0.19		0.48	-0.55	-0.22
Other Stockholder Equity	0.11	-0.85	0.69	-0.66	0.98	0.01	-0.88	-0.05	-0.68	0.66	0.13	0.21	-0.75	-0.84	0.85	-0.28	0.21	0.31	0.27	0.19	-0.94	0.12	0.48		-0.98	-0.86
Total Liab	-0.08	0.78	-0.58	0.58	-0.99	0.06	0.81	0.18	0.62	-0.71	-0.05	-0.19	0.72	0.82	-0.82	0.4	-0.18	-0.22	-0.24	-0.19	0.98	-0.13	-0.55	-0.98		0.79
Property Plant And Equipment Gross	-0.3	0.95	-0.73	0.91	-0.82	-0.18	0.99	-0.19	0.87	-0.48	-0.26	-0.39	0.8	0.71	-0.7	-0.1	-0.39	-0.35	-0.42	-0.3	0.65	-0.04	-0.22	-0.86	0.79

Click cells to compare fundamentals

VTv Therapeutics Account Relationship Matchups

VTv Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	9.3M	14.8M	25.5M	33.2M	11.0M	10.5M
Short Long Term Debt Total	7.1M	915K	932K	716K	529K	502.6K
Other Current Liab	4.8M	4.0M	6.0M	4.7M	6.0M	5.7M
Total Current Liabilities	13.4M	6.4M	8.5M	7.7M	10.6M	15.0M
Total Stockholder Equity	(49.0M)	(80.1M)	(9.7M)	(10.7M)	(24.7M)	(25.9M)
Other Liab	3.9M	3.9M	1.3M	19.4M	17.4M	18.3M
Property Plant And Equipment Net	1.0M	849K	680K	556K	361K	343.0K
Net Debt	5.3M	(4.8M)	(12.5M)	(11.4M)	(8.9M)	(8.5M)
Retained Earnings	(233.5M)	(290.0M)	(248.8M)	(265.5M)	(281.0M)	(295.1M)
Accounts Payable	7.1M	1.9M	1.9M	2.5M	4.1M	4.8M
Cash	1.8M	5.7M	13.4M	12.1M	9.4M	14.4M
Non Current Assets Total	6.4M	7.6M	9.9M	6.1M	361K	343.0K
Non Currrent Assets Other	2.5M	2.9M	(7.6M)	(6.1M)	(5.5M)	(5.3M)
Other Assets	4.8M	2.5M	2.9M	7.2M	8.3M	8.7M
Cash And Short Term Investments	1.8M	5.7M	13.4M	12.1M	9.4M	14.4M
Net Receivables	5K	158K	57K	12.4M	102K	96.9K
Common Stock Shares Outstanding	757.3K	1.2M	1.6M	1.9M	2.1M	1.9M
Short Term Investments	250K	371K	100K	15K	65K	61.8K
Liabilities And Stockholders Equity	9.3M	14.8M	25.5M	33.2M	11.0M	10.5M
Non Current Liabilities Total	44.9M	88.5M	26.7M	36.3M	18.9M	18.0M
Other Current Assets	806K	939K	2.1M	2.5M	1.1M	1.1M
Other Stockholder Equity	183.9M	209.2M	238.2M	254.8M	256.3M	269.2M
Total Liab	58.3M	94.9M	35.2M	44.0M	29.6M	28.1M
Property Plant And Equipment Gross	1.0M	367K	680K	556K	848K	1.1M
Total Current Assets	2.8M	7.2M	15.6M	27.1M	10.7M	16.9M
Short Term Debt	6.3M	394K	624K	532K	529K	502.6K
Property Plant Equipment	1.0M	367K	680K	207K	186.3K	177.0K
Net Tangible Assets	(49.0M)	3.8M	(9.7M)	5.8M	6.7M	7.1M
Short Long Term Debt	6.2M	84K	256K	224K	191K	181.5K
Common Stock Total Equity	435K	641K	541K	1.0M	1.2M	1.3M
Capital Surpluse	150.6M	183.9M	209.2M	253.7M	291.8M	183.4M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for VTv Stock Analysis

When running VTv Therapeutics' price analysis, check to measure VTv Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy VTv Therapeutics is operating at the current time. Most of VTv Therapeutics' value examination focuses on studying past and present price action to predict the probability of VTv Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move VTv Therapeutics' price. Additionally, you may evaluate how the addition of VTv Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC